1. What Structured Investment Products Are and How They Work
Common Product Types
Principal-protected notes promise to return the investor's initial investment at maturity if held to term. That protection depends entirely on the issuer's solvency, not government insurance or any external guarantee. If the issuer defaults, the protection is worthless.
Reverse convertibles pay a high fixed coupon but expose the investor to stock downside. If the reference stock falls below a preset barrier at or before maturity, the investor receives shares worth less than the original investment rather than cash repayment. The coupon compensates for the downside risk the investor has assumed, but that tradeoff is often not clearly communicated.
Barrier notes and autocallable products add further complexity. Returns depend on whether the reference asset crosses specified levels at observation dates. Missing a barrier by a small amount can convert a gain scenario into a significant loss.
Embedded Fees and Liquidity Constraints
Structured products carry costs embedded in the product structure rather than disclosed as a line-item fee. The issuer builds its distribution margin, hedging costs, and profit into the initial pricing. An investor who purchases a product at par may be buying an instrument with immediate negative fair value.
These products also have limited secondary markets. An investor who needs liquidity before maturity may find no buyer or may sell at a significant discount to par. Holding to maturity is often the only way to realize the stated return profile.
A structured product is typically issued as a debt instrument, such as a medium-term note, and pays returns according to a formula tied to the performance of a reference asset. The investor's return is not simply interest. It depends on whether the reference asset stays above a barrier, reaches a threshold, or performs within a specified range over a fixed term.
2. The Regulatory Framework: Sec, Finra, and Regulation Best Interest
Registration and Disclosure under the Securities Act
Structured notes are typically registered under the Securities Act of 1933 through a shelf registration statement. Each specific product is sold under a prospectus supplement describing the terms, the reference asset, the return formula, the issuer's credit risk, and the tax treatment. The adequacy of these disclosures is a recurring subject of SEC staff guidance and enforcement.
The SEC has noted that structured product disclosures often understate risks and use illustrations that favor favorable scenarios. A prospectus supplement that does not fairly present the range of possible outcomes, or that buries material risk factors in dense legal language, may fail to satisfy Securities Act disclosure requirements.
Regulation Best Interest and the Broker-Dealer Standard
SEC Regulation Best Interest, effective June 30, 2020, requires broker-dealers to act in the best interest of retail customers when making a recommendation. It imposes four component obligations: care, disclosure through Form CRS, conflict of interest mitigation, and compliance.
Regulation Best Interest does not impose a full fiduciary duty on broker-dealers. It sets a higher standard than the prior suitability rule but does not require broker-dealers to place the customer's interest above their own in all circumstances. FINRA Rule 2111, which governs suitability in contexts beyond retail customer recommendations, continues to apply alongside Regulation Best Interest.
Investment Adviser Fiduciary Duty
A registered investment adviser recommending structured products owes a fiduciary duty to its client under the Investment Advisers Act of 1940. That duty requires the adviser to act in the client's best interest, provide full and fair disclosure of material information, and eliminate or disclose conflicts of interest. The fiduciary standard is higher than the broker-dealer standard under Regulation Best Interest. An investor who received a structured product recommendation from an RIA may have stronger claims than one who received it from a broker-dealer, depending on how the relationship was structured.
Structured products sold to retail investors are subject to federal securities registration requirements, SEC disclosure rules, and FINRA conduct standards. The applicable standard of conduct depends on whether the seller is a broker-dealer, a registered investment adviser, or both.
3. Disclosure Failures and the Principal Protection Problem
What "Principal Protection" Actually Means
The term principal protected is one of the most frequently misunderstood features of structured products. A principal-protected note promises to return the initial investment only at maturity and only if the issuer remains solvent. When Lehman Brothers collapsed in 2008, holders of Lehman-issued principal-protected structured products lost most of their investments despite the protection label. The protection was an unsecured credit obligation of a bankrupt entity.
A broker or adviser who describes a structured product as safe, low-risk, or equivalent to a CD without disclosing the issuer credit risk and the maturity requirement may have made a material misrepresentation.
Complexity and the Duty to Explain
FINRA Rule 2210 requires that communications with customers be fair, balanced, and not misleading. A marketing document that explains the upside scenario in detail while omitting or minimizing the barrier breach scenario violates this standard.
Investors in structured products often do not understand that their return formula depends on multiple conditions being met simultaneously. Courts and FINRA panels have found liability where brokers failed to ensure that retail customers understood the specific conditions under which principal could be lost.
Most structured product litigation involves a gap between what was communicated to the investor and what the product actually delivered. These gaps arise from omissions, misleading summaries, and marketing materials that emphasize upside without adequately presenting downside risk.
4. Common Legal Claims against Brokers and Issuers
Securities Fraud under Section 10(B) and Rule 10b-5
Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 prohibit material misrepresentations and omissions in connection with the purchase or sale of securities. A structured product investor alleging fraud must plead a material misrepresentation or omission, scienter, a connection with the purchase or sale, reliance, loss causation, and damages. The Private Securities Litigation Reform Act requires heightened pleading of scienter and loss causation.
A misrepresentation about principal protection, an omission of issuer credit risk, or a failure to disclose embedded fees can each form the basis of a 10b-5 claim if the other elements are satisfied.
Suitability and Regulation Best Interest Claims
An investor sold a structured product that did not match their risk tolerance, investment horizon, or financial situation may assert a suitability or Reg BI violation. These claims do not require proof of intent to defraud. A broker who recommended a long-dated barrier note to a retiree needing short-term liquidity, or a leveraged product to a conservative investor, may face liability regardless of whether any affirmative misrepresentation was made.
State Law Claims and the Martin Act
New York's Martin Act, codified at GBL §§ 352-359, gives the Attorney General broad authority to investigate and prosecute securities fraud without requiring proof of intent. It does not create a private right of action. New York investors may bring common law fraud, negligent misrepresentation, and breach of fiduciary duty claims alongside federal securities claims in the same proceeding.
Investors who suffer losses on structured products typically assert claims based on misrepresentation, unsuitability, or breach of fiduciary duty. The strength of these claims depends on what was said at the point of sale, the investor's documented financial profile, and the product's actual risk characteristics.
5. Finra Arbitration and Civil Litigation
How Finra Arbitration Works
Claims under $50,000 may be decided by a single arbitrator under a simplified procedure. Claims over $100,000 are typically heard by a three-person panel. Discovery is more limited than in federal court, and there is no class arbitration. FINRA Rule 12206 bars claims based on events that occurred more than six years before the claim is filed.
FINRA arbitration awards are subject to very limited judicial review. A court may vacate an award only on narrow grounds such as fraud, evident partiality, or arbitrator misconduct.
Civil Litigation for Claims against Issuers
Claims against the issuer of a structured product are more likely to proceed in court than through FINRA arbitration. Section 11 of the Securities Act provides a cause of action for material misstatements or omissions in a registration statement. Unlike a Rule 10b-5 claim, a Section 11 claim does not require proof of scienter or reliance. Plaintiffs need only show a material misstatement or omission and a traceable purchase.
Securities litigation against structured product issuers involves complex damages calculations and often requires expert testimony on the fair value of the product at the time of purchase.
Structured Product Legal Risk Summary
| Claim Type | Legal Basis | Key Element |
|---|---|---|
| Securities fraud | Exchange Act § 10(b); Rule 10b-5 | Material misrepresentation; scienter; loss causation |
| Registration statement defect | Securities Act § 11 | Material misstatement or omission; no scienter required |
| Suitability violation | FINRA Rule 2111; Reg BI | Recommendation inconsistent with customer profile |
| Breach of fiduciary duty | Investment Advisers Act; state law | RIA or dual registrant owed full fiduciary duty |
| State fraud | NY GBL §§ 352-359 (Martin Act) | AG enforcement only; common law claims run separately |
| Arbitration time limit | FINRA Rule 12206 | 6-year eligibility period from date of occurrence |
Most retail investor claims against broker-dealers are resolved through FINRA arbitration rather than in court. Customer agreements typically include arbitration clauses that require disputes to be submitted to FINRA's dispute resolution forum.
6. Frequently Asked Questions
The questions below address the legal issues investors, brokers, and advisers most commonly face in connection with structured investment product disputes.
Regulation Best Interest requires broker-dealers to act in a retail customer's best interest at the time of a recommendation. It is a higher standard than the old suitability rule, but it does not impose a full fiduciary duty. A registered investment adviser owes a fiduciary duty that extends throughout the advisory relationship, not only at the moment of a specific recommendation. An investor working with a dual registrant should clarify which capacity applies to each transaction.
Yes, potentially. Issuer credit risk is material information for any investor buying a principal-protected or capital-at-risk structured product. A broker or adviser who described the product as safe or low-risk without disclosing that protection depends on the issuer's solvency may have made a material misrepresentation. Recovery depends on whether the misrepresentation can be shown, whether the investor relied on it, and whether it caused the loss.
Most claims against broker-dealers are subject to FINRA arbitration under the customer's account agreement. Claims against the issuer, as opposed to the selling broker, may be brought in court if there is no separate arbitration agreement. Section 11 claims under the Securities Act are generally not subject to predispute arbitration agreements under current SEC policy. An investor with claims against both the broker and the issuer may need to pursue separate proceedings simultaneously.
FINRA Rule 12206 provides that no claim is eligible for arbitration if six years have passed from the occurrence or event giving rise to the claim. This is an eligibility rule, not a statute of limitations. A panel may dismiss an otherwise timely claim if the underlying event falls outside the six-year window. Investors who sustained losses several years ago should assess this rule before filing.
The Martin Act gives the New York Attorney General broad enforcement authority over securities fraud without requiring proof of fraudulent intent. It does not create a private right of action, so individual investors cannot sue directly under the statute. New York investors may still bring common law fraud, negligent misrepresentation, and breach of fiduciary duty claims in state court, and may benefit indirectly if an AG investigation results in restitution or injunctive relief.
24 Jun, 2025
